AVIR (Atea Pharma) Net Profit

Official company branding of Atea Pharmaceuticals, Inc. (AVIR)

The current price chart for Atea Pharmaceuticals (AVIR) reflects price action driven by expectations regarding the final stage test results for its oral coronavirus treatment, while R&D costs are already priced into the current value of -0.16. The business focuses on the development of antiviral tablets. Leveraging patents for COVID-19 and Hepatitis C therapies, the company exercises pricing power by charging premium prices due to the convenience of drug administration.

AVIR (Atea Corp) Net Income history from 07/04/2022 to 10/30/2026

Analytical breakdowns and data insights for company Atea Pharmaceuticals, Inc. (AVIR)

- price and consensus price forecast:
Stock Quotes Atea Corp|AVIR - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Atea Corp|AVIR - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Atea Pharmaceuticals|AVIR - Company Net Assets|Market Value to Book Value Ratio ateapharma.com|AVIR - Company Total Assets
- debt and solvency information:
Total Debt to Capital Coefficient Atea Pharmaceuticals|AVIR - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Atea Pharma|AVIR - Company Total Debt|Debts to Book Capitalization Atea Corp|AVIR - Company Long-Term Debt|Short-Term Debt Volume Atea Pharmaceuticals|Quick Ratio ateapharma.com
- net income and valuation multiples indicators:
AVIR - Net Income
Summary company analysis:Atea Pharmaceuticals
Mass-produced product of Atea Pharma

The analyst assesses the credit quality of Atea Pharmaceuticals (AVIR) through the lens of operational efficiency. The issuer's resilience is supported by preparations to bring antiviral drugs to market following the completion of clinical trials. This financial result captures the daily total of all operations, excluding market speculation. The indicator measures real cash returns, separating the fundamental trend from price volatility. The metric's dynamics serve as a benchmark for determining the moment Atea Pharmaceuticals (AVIR) transitions to commercial profitability.

Main competitors

Net Income Gilead Corp|CDTX (Cidara Therapeutics Inc) - Net Profit|Net Profit novavax.com|Net Income CVAC (CureVac)|VALN (Valneva Corp) - Final Profit|Vir Bio - Net Income|TPOXX - Company Net Income|Emergent BioSolutions - Net Profit|Net Financial Result Invivyd, Inc. IVVD|Enanta Pharmaceuticals, Inc. (ENTA) - Company Net Income|Inovio Pharmaceuticals, Inc. - Final Profit|Net Income HLVX|Net Profit Kalaris Tx|Company Net Income Dyadic International (DYAI)|Net Financial Result nanoviricides.com|Net Profit TLPH (Talphera)|Net Profit Cocrystal Pharma Inc COCP|TRAW: Net Income|Dogwood Therapeutics, Inc. - Profit After Payment of Taxes|QLGN: Net Profit|Company Net Income AlloVir (ALVR)|VBIV (VBI Vaccines, Inc.) - Net Profit|Net Profit Virios|Net Income VXRT (Vaxart, Inc.)